Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for treating neuropathic pain in a subject, the method comprising administering to a ~~the~~ subject in need thereof a pharmaceutical composition ~~formulation~~ comprising a therapeutically effective amount of a neublastin polypeptide, wherein the pharmaceutical composition is administered to the subject via systemic delivery ~~at a dosage of between 1 .mu.g/kg to 30,000 .mu.g/kg body weight of the subject, per dose~~.

2. (Currently Amended) The method of claim 1, wherein the neuropathic pain is associated with post-herpetic neuralgia, diabetic neuropathy, or sciatica.

3. (Cancelled)

4. (Currently Amended) The method of claim 1 ~~or 3~~, wherein the pharmaceutical composition ~~neublastin polypeptide~~ is administered via ~~using a delivery system selected from the group consisting of~~ intravenous delivery~~, intramuscular delivery, intrapulmonary delivery, subcutaneous delivery, and intraperitoneal delivery~~.

5. (Currently Amended) The method of claim 1 ~~or 3~~, wherein the pharmaceutical composition ~~neublastin polypeptide~~ is administered via ~~intramuscular delivery or~~ subcutaneous delivery.

6-9. (Cancelled)

10. (Currently Amended) The method of claim 1, ~~or 3~~ wherein the neublastin polypeptide is modified with a derivative moiety to have an extended residence time ~~and/~~or increased concentration in body fluids.

11. (Currently Amended) The method of claim 10, wherein the derivative moiety is a polyethylene glycol moiety.

12. (Currently Amended) The method of claim 10, wherein the derivative moiety is selected from the group consisting of aliphatic esters, amides, N-acyl-derivatives, or O-acyl derivatives.

13-26. (Cancelled)

27. (Currently Amended) The method of claim ~~claims~~ 1 ~~or 13~~, wherein said neuropathic pain is associated with infection of said subject by a virus.

28. (Currently Amended) The method of claim 27, wherein said virus is selected from the group consisting of a herpes virus, a human immunodeficiency virus (HIV), and a papilloma virus.

29. (Currently Amended) The method of claim ~~claims~~ 1 ~~or 13~~, wherein said neuropathic pain is neuropathic pain associated with administration of a therapeutic agent.

30. (Original) The method of claim 29, wherein said therapeutic agent is an anti-cancer agent.

31. (Currently Amended) The method of claim 30, wherein the anti-cancer agent is selected from the group consisting of taxol, taxotere, cisplatin, nocodazole, vincristine, vindesine and vinblastine.

32. (Original) The method of claim 29, wherein said therapeutic agent is an anti-viral agent.

33. (Original) The method of claim 32, wherein said anti-viral agent is selected from the group consisting of ddI, DDC, d4T, foscarnet, dapsone, metronidazole, and isoniazid.

34. (Currently Amended) The method of claim 1 ~~or 13~~, wherein said neuropathic pain is due to injury associated with trauma.

35. (Currently Amended) The method of claim 1 ~~or 13~~, wherein said neuropathic pain is characterized by allodynia.

36. (Currently Amended) The method of claim 1 ~~or 13~~, wherein said neuropathic pain is hyperalgesic pain.

37. (Currently Amended) The method of claim 36, wherein the hyperalgesic pain is thermal hyperalgesic pain ~~hyperalgesia~~.

38. (Currently Amended) The method of claim 1 ~~or 13~~, wherein said neuropathic pain is phantom pain.

39-56. (Cancelled)

57. (New) The method of claim 35, wherein the allodynia is tactile allodynia.

58. (New) The method of claim 35, wherein the pharmaceutical composition is administered via subcutaneous delivery.

59. (New) The method of claim 35, wherein the pharmaceutical composition is administered via intravenous delivery.

60. (New) The method of claim 36, wherein the pharmaceutical composition is administered via subcutaneous delivery.

61. (New) The method of claim 36, wherein the pharmaceutical composition is administered via intravenous delivery.

62. (New) The method of claim 37, wherein the pharmaceutical composition is administered via subcutaneous delivery.

63. (New) The method of claim 37, wherein the pharmaceutical composition is administered via intravenous delivery.

64. (New) The method of claim 57, wherein the pharmaceutical composition is administered via subcutaneous delivery.

65. (New) The method of claim 57, wherein the pharmaceutical composition is administered via intravenous delivery.

66. (New) The method of claim 1, wherein the neublastin polypeptide exhibits neurotrophic activity and comprises an amino acid sequence that is at least 85% identical to amino acids 28-140 of SEQ ID NO:2.

67. (New) The method of claim 1, wherein the neublastin polypeptide exhibits neurotrophic activity and comprises an amino acid sequence that is at least 90% identical to amino acids 28-140 of SEQ ID NO:2.

68. (New) The method of claim 1, wherein the neublastin polypeptide exhibits neurotrophic activity and comprises an amino acid sequence that is at least 95% identical to amino acids 28-140 of SEQ ID NO:2.

69. (New) The method of claim 66, wherein the neublastin polypeptide comprises amino acids 42-140 of SEQ ID NO:2.

70. (New) The method of claim 66, wherein the neublastin polypeptide comprises amino acids 37-140 of SEQ ID NO:2.